Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination

被引:3
|
作者
van den Biggelaar, Anita H. J. [1 ]
Richmond, Peter C. [2 ]
Fuery, Angela [2 ,5 ]
Anderson, Denise [1 ]
Opa, Christine [3 ]
Saleu, Gerard [3 ]
Lai, Mildred [3 ]
Francis, Jacinta P. [3 ]
Alpers, Michael P. [4 ]
Pomat, William S. [3 ]
Lehmann, Deborah [1 ]
机构
[1] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia
[2] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia
[3] Papua New Guinea Inst Med Res, Goroka, Eastern Highlan, Papua N Guinea
[4] Curtin Univ, Sch Hlth Sci, Int Hlth, Perth, WA, Australia
[5] Baylor Coll Med, Houston, TX 77030 USA
来源
PLOS ONE | 2017年 / 12卷 / 10期
基金
英国医学研究理事会; 英国惠康基金; 澳大利亚国家健康与医学研究理事会;
关键词
RESPIRATORY-TRACT INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; IMMUNE-RESPONSE; HYPORESPONSIVENESS; IMMUNOGENICITY; DISEASE; PERSISTENCE; 7-VALENT; EFFICACY; BOOSTER;
D O I
10.1371/journal.pone.0185877
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Trial design In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 9 months of age. We here studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in these children at 3-5 years of age (n = 132), and in 121 community controls of a similar age with no prior pneumococcal vaccination. Methods Circulating IgG antibody titers to all PCV7 and PPV23-only serotypes 2, 5 and 7F were measured before and after challenge with 1/5 th of a normal PPV23 dose. Serotype-specific memory B-cells were enumerated at 10 months and 3-5 years of age for a subgroup of study children. Results Serotype-specific IgG antibody titers before and after challenge were similar for children who received PCV7/PPV23, PPV23 only, or no pneumococcal vaccines. Before challenge, at least 89% and 59% of children in all groups had serotype-specific titers similar to 0.35 mu g/ml and similar to 1.0 mu g/ml, respectively. Post-challenge antibody titers were higher or similar to pre-challenge titers for most children independent of pneumococcal vaccination history. The rise in antibody titers was significantly lower when pre-challenge titers were higher. Overall the relative number of serotype-specific memory B-cells remained the same or increased between 10 months and 3-5 years of age, and there were no differences in serotype-specific memory B-cell numbers at 3-5 years of age between the three groups. Conclusions Immunity induced by PCV7 and/or PPV23 immunization in infancy does not exceed that of naturally acquired immunity in 3-5-year-old children living in a highly endemic area. Also, there was no evidence that PPV23 immunization in the first year of life following PCV7 priming induces longer-term hypo-responsiveness.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses
    Schaballie, H.
    Wuyts, G.
    Dillaerts, D.
    Frans, G.
    Moens, L.
    Proesmans, M.
    Vermeulen, F.
    De Boeck, K.
    Meyts, I.
    Bossuyt, X.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2016, 185 (02) : 180 - 189
  • [2] A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children
    Obaro, SK
    Huo, ZM
    Banya, WAS
    Henderson, MC
    Monteil, MA
    Leach, A
    Greenwood, BM
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (12) : 1135 - 1140
  • [3] Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Frenck, Robert W.
    Treanor, John
    Jansen, Kathrin U.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3594 - 3602
  • [4] Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes
    Boelsen, Laura K.
    Dunne, Eileen M.
    Lamb, Karen E.
    Bright, Kathryn
    Cheung, Yin Bun
    Tikoduadua, Lisi
    Russell, Fiona M.
    Mulholland, E. Kim
    Licciardi, Paul V.
    Satzke, Catherine
    VACCINE, 2015, 33 (42) : 5708 - 5714
  • [5] Long-term Immune Responses to Pneumococcal Conjugate Vaccines in Children Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine
    Klein, Nicola P.
    Ensor, Kathy
    Jouve, Sylvie
    Northington, Robert
    Moscariello, Michele
    McGovern, Paul C.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (09) : 990 - 997
  • [6] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Peterson, James T.
    Stacey, Helen L.
    MacNair, John E.
    Li, Jianing
    Hartzel, Jonathan S.
    Sterling, Tina M.
    Benner, Patrice
    Tamms, Gretchen M.
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 540 - 548
  • [7] A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine
    Martinon-Torres, Federico
    Martinez, Silvina Natalini
    Kline, Mary J.
    Drozd, Jelena
    Trammel, James
    Peng, Yahong
    Giardina, Peter C.
    Gruber, William C.
    Watson, Wendy
    Bickham, Kara
    Tamimi, Noor
    VACCINE, 2025, 53
  • [8] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Jackson, Lisa A.
    Gurtman, Alejandra
    Rice, Kathryn
    Pauksens, Karlis
    Greenberg, Richard N.
    Jones, Thomas R.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3585 - 3593
  • [9] Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial
    Pomat, William S.
    van den Biggelaar, Anita H. J.
    Phuanukoonnon, Suparat
    Francis, Jacinta
    Jacoby, Peter
    Siba, Peter M.
    Alpers, Michael P.
    Reeder, John C.
    Holt, Patrick G.
    Richmond, Peter C.
    Lehmann, Deborah
    PLOS ONE, 2013, 8 (02):
  • [10] A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age
    Jagne, Isatou
    von Mollendorf, Claire
    Wee-Hee, Ashleigh
    Ortika, Belinda
    Satzke, Catherine
    Russell, Fiona M.
    VACCINE, 2023, 41 (19) : 3028 - 3037